Project Grant HT94252410117
Award Date
7/1/24
Completion Date
6/30/26
Dollars Obligated
$963K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hanover, NH 03755, USA
Similar Awards
The University of Massachusetts Medical School has been awarded a $987,615 federal Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 30, 2024 to September 29, 2026, supports the "Development of Chimeric Antigen Receptor T Regulatory Cells (CAR Tregs) for the Treatment of Amyotrophic Lateral Sclerosis." This project aims to advance research into new therapeutic approaches for...
The U.S. Defense Health Agency awarded a $1,134,000 Project Grant to President and Fellows of Harvard College (Harvard University) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "NOVEL BRAIN SHUTTLE-MEDIATED ANTI-TDP-43 THERAPEUTICS FOR AMYOTROPHIC LATERAL SCLEROSIS," supports research to develop novel treatments for amyotrophic lateral sclerosis (ALS) by leveraging brain shuttle technologies. The project will be conducted at Harvard...
The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
This $704,198 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by Trustees of Dartmouth College to develop chimeric antigen receptor (CAR) T regulatory cells (Tregs) targeted to amyloid-beta for the treatment of Alzheimer's disease. The goal is to engineer CAR Tregs that can persist in the central nervous system (CNS) and rebalance cerebral immunity, promote amyloid-beta clearance, and limit neuronal damage associated with Alzheimer's...
The Defense Health Agency awarded a $997,821 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Trustees of Dartmouth College. The grant, with a performance period from November 1, 2024 to October 31, 2027, will support research on the "Pathogenic Role of Neutrophil Subpopulations in Lupus Nephritis." Dartmouth College will serve as the primary awardee, collaborating with sub-grantees The Johns Hopkins University and Dartmouth-Hitchcock Clinic to...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $798,272 to The Johns Hopkins University to test the use of Wnt inhibitors as a therapeutic to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The award has a performance period from March 15, 2025 to March 14, 2027 and will support advanced biomedical research focused on developing innovative medical solutions...
The Department of the Army Medical Command awarded a $879,721 project grant to The Trustees of Columbia University in the City of New York under the Military Medical Research and Development (CFDA 12.420) federal grant program. The purpose of this 24-month award, with a performance period from April 1, 2025 to March 31, 2027, is to evaluate the efficacy of small molecule ferroptosis inhibitors in a preclinical model of amyotrophic lateral sclerosis (ALS). This research initiative aims to develop...
The University of Denver was awarded a $877,397 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "SYNTHETIC PROTEIN MIMETICS-BASED SPECIFIC TARGETING AND DEGRADATION OF TDP-43 AGGREGATION ASSOCIATED WITH ALS". This 2-year grant, with an award date of March 1, 2024 and a completion date of February 28, 2026, will support the university's research efforts to develop new treatments for amyotrophic...
The Department of the Army Medical Command awarded a $2,311,734 Project Grant under the Military Medical Research and Development federal grant program (CFDA 12.420) to the Denver Research Institute (DRI), a non-profit research organization. The grant, titled "DEVELOPMENT AND EVALUATION OF A CARE PATHWAY FOR EVALUATION AND MANAGEMENT OF THE RESPIRATORY SYNDROMES OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) [CAPRESA]," will fund the development and evaluation of a care pathway for managing...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...